Top

BMC Gastroenterology

Published in:

Open Access 01-12-2019 | Rectal Cancer | Research article

Impact of primary colorectal Cancer location on the KRAS status and its prognostic value

Authors: Ming-zhi Xie, Ji-lin Li, Zheng-min Cai, Ke-zhi Li, Bang-li Hu

Published in: BMC Gastroenterology | Issue 1/2019

Abstract

Background

Colorectal cancer (CRC) originating from the right-sided or left-sided colon is distinct clinicopathological entity. The KRAS status and its prognostic value in CRC remain controversial. This study aimed to investigate the association of KRAS status with clinicopathological features and prognostic value in CRC.

Methods

178 colon cancer and 145 rectal cancer patients were enrolled. KRAS mutation test was performed on paraffin-embedded tumor samples using PCR methods. The colon cancer was divided into right-sided colon cancer (RCC) and left-sided colon cancer (LCC). Studies that reported the association of KRAS mutation with CRC clinical features and prognosis in databases were searched prior to 2018. The data of the present study was combined with the data of published studies using meta-analysis methods.

Results

No significant difference between colon cancer and rectal cancer regarding the KRAS status. The KRAS mutation was much frequent in RCC than in LCC (p = 0.010). 17 studies with 11,385 colon cancer patients were selected, the pooled results of our data and previous published data showed that KRAS mutation was more frequent in RCC compared with in LCC (p < 0.01); KRAS mutation was not associated with the prognosis in RCC patient; however, KRAS mutation indicated a poor prognosis in LCC patients compared with KRAS wild type (p < 0.01).

Conclusion

KRAS status has no difference between colon cancer and rectal cancer. KRAS mutation was more frequent in RCC than in LCC, and associated with a poor prognosis in LCC patients, but not in RCC patients.

Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93. https://doi.org/10.3322/caac.21395.CrossRefPubMed

Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69–80. https://doi.org/10.1016/j.ejca.2017.07.016.CrossRefPubMedPubMedCentral

Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Tumorigenesis VVE. RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418(6901):934. https://doi.org/10.1038/418934a.CrossRefPubMed

Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001;85(5):692–6. https://doi.org/10.1054/bjoc.2001.1964.CrossRefPubMedPubMedCentral

Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3(11):e3698. https://doi.org/10.1371/journal.pone.0003698.CrossRefPubMedPubMedCentral

Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. https://doi.org/10.1056/NEJMoa0805019.CrossRefPubMed

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812–20. https://doi.org/10.1001/jama.2010.1535.CrossRefPubMed

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65. https://doi.org/10.1056/NEJMoa0804385.CrossRefPubMed

Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, et al. Molecular profiling of patients with advanced colorectal Cancer: Princess Margaret Cancer Centre experience. Clin Colorectal Cancer. 2018;17(1):73–9. https://doi.org/10.1016/j.clcc.2017.10.010.CrossRefPubMed

10.

Cushman-Vokoun AM, Stover DG, Zhao Z, Koehler EA, Berlin JD, Vnencak-Jones CL. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Clin Colorectal Cancer. 2013;12(3):168–78. https://doi.org/10.1016/j.clcc.2013.04.005.CrossRefPubMedPubMedCentral

11.

Natsume S, Yamaguchi T, Takao M, Iijima T, Wakaume R, Takahashi K, et al. Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. Jpn J Clin Oncol. 2018;48(7):609–18. https://doi.org/10.1093/jjco/hyy069.CrossRefPubMed

12.

Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, et al. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes’ C colon cancer. Am J Gastroenterol. 2000;95(10):2953–7. https://doi.org/10.1111/j.1572-0241.2000.02327.x.CrossRefPubMed

13.

Gao XH, Yu GY, Gong HF, Liu LJ, Xu Y, Hao LQ, et al. Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. Sci Rep. 2017;7(1):7882. https://doi.org/10.1038/s41598-017-08413-z.CrossRefPubMedPubMedCentral

14.

Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol. 2001;27(1):80–7. https://doi.org/10.1053/ejso.2000.1029.CrossRefPubMed

15.

Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, et al. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer. 2012;118(24):6243–52. https://doi.org/10.1002/cncr.27666.CrossRefPubMed

16.

Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012;106(2):123–9. https://doi.org/10.1002/jso.23063.CrossRefPubMed

17.

Kim HS, Heo JS, Lee J, Lee JY, Lee MY, Lim SH, et al. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. BMC Cancer. 2016;16:120. https://doi.org/10.1186/s12885-016-2141-4.CrossRefPubMedPubMedCentral

18.

Charlton ME, Kahl AR, Greenbaum AA, Karlitz JJ, Lin C, Lynch CF, et al. KRAS testing, tumor location, and survival in patients with stage IV colorectal Cancer: SEER 2010-2013. J Natl Compr Cancer Netw. 2017;15(12):1484–93. https://doi.org/10.6004/jnccn.2017.7011.CrossRef

19.

Chang YY, Lin PC, Lin HH, Lin JK, Chen WS, Jiang JK, et al. Mutation spectra of RAS gene family in colorectal cancer. Am J Surg. 2016;212(3):537–44 e3. https://doi.org/10.1016/j.amjsurg.2016.02.013.CrossRefPubMed

20.

Hou Y, Li SB, Shi XQ, Fu GH, Wu J. Retrospective analysis of KRAS, NRAS and BRAF gene mutations and clinicopathological features in patients with colorectal cancer. J Shanghai Jiaotong Uni: Med Sci. 2018;38(1):4–9.

21.

Kim ST, Lee SJ, Lee J, Park SH, Park JO, Lim HY, et al. The impact of microsatellite instability status and sidedness of the primary tumor on the effect of Cetuximab-containing chemotherapy in patients with metastatic colorectal Cancer. J Cancer. 2017;8(14):2809–15. https://doi.org/10.7150/jca.18286.CrossRefPubMedPubMedCentral

22.

Kodaz H, Hacibekiroglu I, Erdogan B, Turkmen E, Tozkir H, Albayrak D, et al. Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Mol Clin Oncol. 2015;3(1):179–84. https://doi.org/10.3892/mco.2014.448.CrossRefPubMed

23.

Sasaki K, Margonis GA, Wilson A, Kim Y, Buettner S, Andreatos N, et al. Prognostic implication of KRAS status after hepatectomy for colorectal liver metastases varies according to primary colorectal tumor location. Ann Surg Oncol. 2016;23(11):3736–43. https://doi.org/10.1245/s10434-016-5361-6.CrossRefPubMed

24.

Sun P, Wan JY, Wu LH, Xiao Y. Relationship between KRAS/NRAS/BRAF gene mutations and clinical pathological characteristics in colorectal cancer. Chin J General Surg. 2016;31(1):50–4.

25.

Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol. 2015;21(5):1595–605. https://doi.org/10.3748/wjg.v21.i5.1595.CrossRefPubMedPubMedCentral

26.

Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 2009;219(4):435–45. https://doi.org/10.1002/path.2625.CrossRefPubMed

27.

Tong JH, Lung RW, Sin FM, Law PP, Kang W, Chan AW, et al. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther. 2014;15(6):768–76. https://doi.org/10.4161/cbt.28550.CrossRefPubMedPubMedCentral

28.

von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 2014;140(9):1607–14. https://doi.org/10.1007/s00432-014-1678-3.CrossRef

29.

Zhu XL, Cai X, Zhang L, Yang F. KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese. Chin J Pathol. 2012;41(9):584–9.

30.

Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol. 2008;23(3):418–23. https://doi.org/10.1111/j.1440-1746.2007.04923.x.CrossRefPubMed

31.

Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261–70. https://doi.org/10.1200/JCO.2010.30.1366.CrossRefPubMed

32.

Simon MS, Thomson CA, Pettijohn E, Kato I, Rodabough RJ, Lane D, et al. Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative. Cancer Epidemiol Biomark Prev. 2011;20(7):1368–78. https://doi.org/10.1158/1055-9965.EPI-11-0027.CrossRef

33.

Virk R, Gill S, Yoshida E, Radley S, Salh B. Racial differences in the incidence of colorectal cancer. Can J Gastroenterol. 2010;24(1):47–51.CrossRefPubMedPubMedCentral

Title: Impact of primary colorectal Cancer location on the KRAS status and its prognostic value
Authors: Ming-zhi Xie
Ji-lin Li
Zheng-min Cai
Ke-zhi Li
Bang-li Hu
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Rectal Cancer
Rectal Cancer
Colorectal Cancer
Colorectal Cancer
Colon Cancer
Colon Cancer
Published in: BMC Gastroenterology / Issue 1/2019
Electronic ISSN: 1471-230X
DOI: https://doi.org/10.1186/s12876-019-0965-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of primary colorectal Cancer location on the KRAS status and its prognostic value

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease – a scoping review and practical implications

Clinical value of DPOC for detecting and removing residual common bile duct stones (video)

A novel collagen area fraction index to quantitatively assess bowel fibrosis in patients with Crohn’s disease

The incidence, etiologies, outcomes, and predictors of mortality of acute liver failure in Thailand: a population-base study

Candidate single nucleotide polymorphisms of irritable bowel syndrome: a systemic review and meta-analysis

Interactive decision support for esophageal adenocarcinoma screening and surveillance

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page